ALXO
Companies
NASDAQ
Alx Oncology Holdings Inc.
Health Care
$0.49
-$1.18 (-70.84%)
Price Chart
Overview
About ALXO
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Market Cap
$469.4M
Volume
199.4K
Avg. Volume
523.0K
P/E Ratio
-0.19350553
Dividend Yield
0.00%
Employees
65.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.16
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ALXO shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$469.4M
Volume199.4K
P/E Ratio-0.19
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 7, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025